OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
New Daily Persistent Headache
Interventions
DRUG

OnabotulinumtoxinA

155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).

Trial Locations (1)

10019

Roosevelt Hospital Headache Institute, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

St. Luke's-Roosevelt Hospital Center

OTHER

NCT01920945 - OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study | Biotech Hunter | Biotech Hunter